David D. Chang - May 24, 2021 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: President and CEO, Director
Signature: /s/ Veer Bhavnagri, Attorney-in-Fact
Stock symbol: ALLO
Transactions as of: May 24, 2021
Transactions value $: $499,410
Form type: 4
Date filed: 5/26/2021, 08:00 AM
Next filing: Mar 17, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALLO	Common Stock	Options Exercise	$499K	+27.4K	+1.2%	$18.22^*	2.31M	May 24, 2021	Direct
holding	ALLO	Common Stock						1.2M	May 24, 2021	See footnote	F1
holding	ALLO	Common Stock						856K	May 24, 2021	See footnote	F2
holding	ALLO	Common Stock						856K	May 24, 2021	See footnote	F3

Showing 1 to 4 of 4 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALLO	Stock Option (Right to Buy)	Options Exercise	$0	-27.4K	-4.82%	$0.00	541K	May 24, 2021	Common Stock	27.4K	$18.22	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Securities held in the name of the Chang 2006 Family Trust.
F2	Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F3	Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F4	25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.